Metopimazine

Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks[1][2][3].

Product Specifications

CAS Number

[14008-44-7]

Product Name Alternative

EXP999; RP9965

UNSPSC

12352005

Hazard Statement

H302

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/metopimazine.html

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N)C1CCN(CC1)CCCN2C3=C(SC4=CC=C(C=C24)S(=O)(C)=O)C=CC=C3

Molecular Formula

C22H27N3O3S2

Molecular Weight

445.60

Precautions

H302

References & Citations

[1]Victoire Roussel, et al. Estimating the excess of inappropriate prescriptions of anti-dopaminergic anti-emetics during acute gastroenteritis epidemics in France. Pharmacoepidemiol Drug Saf. 2013 Oct;22 (10) :1080-5.|[2]Mozgova O, et al. A new spectrophotometric method for the quantitative determination of Metopimazine based on the absorbance of its sulfoxide[J]. Chemical Papers, 2024, 78 (11) : 6585-6591.|[3]Jolliet P, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007 Jul;56 (1) :11-7.